Yi-Sheng Chen1, Wei-Di Chen2, Yin-Huei Chen3, Akbarshakh Akhmerov4, Hsiang-Chi Wang5, Kuan-Cheng Chang6,7,8,9, Yen-Nien Lin6,7,8,9,4. 1. Department of Internal Medicine, Far Eastern Memorial Hospital, New Taipei City, Taiwan. 2. Department of Chinese Medicine. 3. Division of Endocrinology and Metabolism, Department of Internal Medicine, China Medical University Hospital, China Medical University. 4. Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA, 90048, USA. 5. Management Office for Health Data, China Medical University Hospital, Taichung. 6. Graduate Institute of Clinical Medical Science, China Medical University. 7. Division of Cardiovascular Medicine, Department of Medicine, China Medical University Hospital. 8. Cardiovascular Research Laboratory, China Medical University Hospital. 9. College of Medicine, China Medical University.
Abstract
BACKGROUND: Premature ventricular complexes (PVC) may cause ventricular dyssynchrony and lead to left atrium and ventricle mechanical abnormalities. Although ventricular cardiomyopathy due to PVCs has been well studied, little is known about atrial adaptation to PVCs. OBJECTIVES: To assess atrial and ventricular responses to PVC therapy. METHODS: All patients with PVC burden > 5000 beats/day on Holter monitoring were enrolled. Baseline demographics, comorbidities, social habits, Holter parameters, and echocardiography profiles were recorded. Follow-up Holter electrocardiography (ECG) and echocardiography data were compared between PVC-treated and non-treated patients. RESULTS: Two hundred and eighty-six patients were enrolled, of whom 139 received PVC treatment. Among the treated patients, 125 who underwent follow up Holter ECG or echocardiography were included in the final analysis. The mean follow-up times of Holter ECG and echocardiography were 9.40 ± 6.70 and 9.40 ± 5.52 months, respectively. Ventricular arrhythmic burden was significantly reduced in the treatment group (16.46% vs. 13.41%, p = 0.041) but was significantly increased in the observation group (7.58% vs. 14.95%, p = 0.032). A significant increase in left atrial (LA) diameter (36.94 mm vs. 39.46 mm, p = 0.025) and reduction in left ventricular ejection fraction (LVEF) (57.26% vs. 53.8%, p = 0.040) were noted in the observation group. There were no significant differences in supraventricular arrhythmic burden in the observation group and LA diameter and LVEF in the treatment group. CONCLUSIONS: PVC therapy effectively reduced ventricular arrhythmic burden in the treatment group on follow-up. Our data suggest that PVC treatment may prevent LA dilation and LVEF decline.
BACKGROUND: Premature ventricular complexes (PVC) may cause ventricular dyssynchrony and lead to left atrium and ventricle mechanical abnormalities. Although ventricular cardiomyopathy due to PVCs has been well studied, little is known about atrial adaptation to PVCs. OBJECTIVES: To assess atrial and ventricular responses to PVC therapy. METHODS: All patients with PVC burden > 5000 beats/day on Holter monitoring were enrolled. Baseline demographics, comorbidities, social habits, Holter parameters, and echocardiography profiles were recorded. Follow-up Holter electrocardiography (ECG) and echocardiography data were compared between PVC-treated and non-treated patients. RESULTS: Two hundred and eighty-six patients were enrolled, of whom 139 received PVC treatment. Among the treated patients, 125 who underwent follow up Holter ECG or echocardiography were included in the final analysis. The mean follow-up times of Holter ECG and echocardiography were 9.40 ± 6.70 and 9.40 ± 5.52 months, respectively. Ventricular arrhythmic burden was significantly reduced in the treatment group (16.46% vs. 13.41%, p = 0.041) but was significantly increased in the observation group (7.58% vs. 14.95%, p = 0.032). A significant increase in left atrial (LA) diameter (36.94 mm vs. 39.46 mm, p = 0.025) and reduction in left ventricular ejection fraction (LVEF) (57.26% vs. 53.8%, p = 0.040) were noted in the observation group. There were no significant differences in supraventricular arrhythmic burden in the observation group and LA diameter and LVEF in the treatment group. CONCLUSIONS: PVC therapy effectively reduced ventricular arrhythmic burden in the treatment group on follow-up. Our data suggest that PVC treatment may prevent LA dilation and LVEF decline.
Entities:
Keywords:
Antiarrhythmic agent; Cardiomyopathy; Left atrium; Left ventricle; Premature ventricular complex; Radiofrequency catheter ablation
Authors: Gbolahan O Ogunbayo; Richard Charnigo; Yousef Darrat; Jignesh Shah; Ripa Patel; John Suffredini; William Wilson; Kevin Parrott; Nathan Kusterer; Luigi Di Biase; Andrea Natale; Gustavo Morales; Claude S Elayi Journal: Am J Cardiol Date: 2018-07-19 Impact factor: 2.778
Authors: Sana M Al-Khatib; William G Stevenson; Michael J Ackerman; William J Bryant; David J Callans; Anne B Curtis; Barbara J Deal; Timm Dickfeld; Michael E Field; Gregg C Fonarow; Anne M Gillis; Christopher B Granger; Stephen C Hammill; Mark A Hlatky; José A Joglar; G Neal Kay; Daniel D Matlock; Robert J Myerburg; Richard L Page Journal: Circulation Date: 2018-09-25 Impact factor: 29.690
Authors: Diego Penela; Carine Van Huls Van Taxis; Carine Van Huls Vans Taxis; Luis Aguinaga; Juan Fernández-Armenta; Lluis Mont; Maria Angels Castel; Magda Heras; Jose María Tolosana; Marta Sitges; Augusto Ordóñez; Josep Brugada; Katja Zeppenfeld; Antonio Berruezo Journal: J Am Coll Cardiol Date: 2013-07-10 Impact factor: 24.094
Authors: Sunil K Agarwal; Gerardo Heiss; Pentti M Rautaharju; Eyal Shahar; Mark W Massing; Ross J Simpson Journal: Stroke Date: 2010-02-18 Impact factor: 7.914